During the past decade, ULSAM, EPE - Hospital Conde de Bertiandos conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 4 clinical trials were completed, i.e. on average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 4 clinical trials were completed. i.e. 80% of trials that started reached the finish line.

Out of the total clinical trials conducted in "ULSAM, EPE - Hospital Conde de Bertiandos" #1 sponsor was "Janssen Research & Development, LLC" with 3 trials, followed by "Boehringer Ingelheim" with 2 trials sponsored, "Pfizer" with 2 trials sponsored, "Janssen Pharmaceutica N.V., Belgium" with 1 trials sponsored and "Soraia Azevedo" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "ULSAM, EPE - Hospital Conde de Bertiandos" #1 collaborator was "Eli Lilly and Company" with 2 trials as a collaborator, "CHRC-Comprehensive Health Research Centre, FCM|NMS, UNL" with 1 trials as a collaborator, "Centro Hospitalar Baixo Vouga - Hospital Infante D. Pedro" with 1 trials as a collaborator, "Centro Hospitalar Lisboa Ocidental Hospital Egas Moniz" with 1 trials as a collaborator and "Centro Hospitalar Médio Tejo - Hospital Rainha Santa Isabel - Torres Novas" with 1 trials as a collaborator. Other collaborators include 3 different institutions and companies that were collaborators in the rest 13 trials.

According to Clinical.Site data, the most researched conditions in "ULSAM, EPE - Hospital Conde de Bertiandos" are "Arthritis, Psoriatic" (2 trials), "Arthritis, Rheumatoid" (1 trials), "Axial Spondyloarthritis" (1 trials), "Calcific Tendinitis" (1 trials) and "Lung Diseases, Interstitial" (1 trials). Many other conditions were trialed in "ULSAM, EPE - Hospital Conde de Bertiandos" in a lesser frequency.

Most popular intervention types in "ULSAM, EPE - Hospital Conde de Bertiandos" are "Drug" (9 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Nintedanib" (2 trials), "Guselkumab" (1 trials), "Guselkumab 100 mg" (1 trials) and "Investigational Medical Product (IMP) administered in parent study" (1 trials). Other intervention names were less common.

The vast majority of trials in "ULSAM, EPE - Hospital Conde de Bertiandos" are 10 trials for "All" genders.

Currently, there are NaN active trials in "ULSAM, EPE - Hospital Conde de Bertiandos". undefined are not yet recruiting, 4 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in ULSAM, EPE - Hospital Conde de Bertiandos, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in ULSAM, EPE - Hospital Conde de Bertiandos, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".